Integrin alpha4beta1 antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Integrin alpha4beta1 antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Integrin alpha4beta1 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Integrin alpha4beta1 antagonists: Overview
Integrins are cell adhesion and signalling proteins crucial to a wide range of biological functions. Effective marketed treatments have successfully targeted integrins ?IIb?3, ?4?7/?4?1 and ?L?2 for cardiovascular diseases, inflammatory bowel disease/multiple sclerosis and dry eye disease, respectively. The related integrins ?4?7 and ?4?1 are therapeutic targets that are expressed on leukocytes and also recognize short peptide sequences, one of which is Leu–Asp–Val (LDV). There is some preclinical evidence that ?3?1 (ref.82), ?4?1 (ref.83) and ?8?1 integrins play a role in pulmonary fibrosis, and that ?v?8 is important in small airway fibrosis associated with chronic obstructive pulmonary fibrosis and asthma.
Report Highlights
This segment of the Integrin alpha4beta1 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Integrin alpha4beta1 antagonists Emerging Drugs
Further product details are provided in the report……..
Integrin alpha4beta1 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Integrin alpha4beta1 antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Integrin alpha4beta1 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Integrin alpha4beta1 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Integrin alpha4beta1 antagonists drugs.
Integrin alpha4beta1 antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Integrin alpha4beta1 antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Integrin alpha4beta1 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Integrin alpha4beta1 antagonists: Overview
Integrins are cell adhesion and signalling proteins crucial to a wide range of biological functions. Effective marketed treatments have successfully targeted integrins ?IIb?3, ?4?7/?4?1 and ?L?2 for cardiovascular diseases, inflammatory bowel disease/multiple sclerosis and dry eye disease, respectively. The related integrins ?4?7 and ?4?1 are therapeutic targets that are expressed on leukocytes and also recognize short peptide sequences, one of which is Leu–Asp–Val (LDV). There is some preclinical evidence that ?3?1 (ref.82), ?4?1 (ref.83) and ?8?1 integrins play a role in pulmonary fibrosis, and that ?v?8 is important in small airway fibrosis associated with chronic obstructive pulmonary fibrosis and asthma.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Integrin alpha4beta1 antagonists R&D. The therapies under development are focused on novel approaches for Integrin alpha4beta1 antagonists.
This segment of the Integrin alpha4beta1 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Integrin alpha4beta1 antagonists Emerging Drugs
- Natalizumab: Biogen
- AXR 159: AxeroVision
Further product details are provided in the report……..
Integrin alpha4beta1 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Integrin alpha4beta1 antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Integrin alpha4beta1 antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Integrin alpha4beta1 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Integrin alpha4beta1 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Integrin alpha4beta1 antagonists drugs.
Integrin alpha4beta1 antagonists Report Insights
- Integrin alpha4beta1 antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Integrin alpha4beta1 antagonists drugs?
- How many Integrin alpha4beta1 antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Integrin alpha4beta1 antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Integrin alpha4beta1 antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Integrin alpha4beta1 antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biogen
- AxeroVision
- Polpharma Biologics
- EA Pharma
- BioMAS
- Feramda
- Natalizumab
- AXR-159
- PB-006
- AJM 300
- AS 101
- BIIB 107
- SAS
Introduction
Executive Summary
Integrin alpha4beta1 antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Integrin alpha4beta1 antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
PB-006: Polpharma Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AXR 159: AxeroVision
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BIIB 107: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SAS: Feramda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Integrin alpha4beta1 antagonists Key Companies
Integrin alpha4beta1 antagonists Key Products
Integrin alpha4beta1 antagonists- Unmet Needs
Integrin alpha4beta1 antagonists- Market Drivers and Barriers
Integrin alpha4beta1 antagonists- Future Perspectives and Conclusion
Integrin alpha4beta1 antagonists Analyst Views
Integrin alpha4beta1 antagonists Key Companies
Appendix
Executive Summary
Integrin alpha4beta1 antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Integrin alpha4beta1 antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
PB-006: Polpharma Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AXR 159: AxeroVision
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BIIB 107: Biogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SAS: Feramda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Integrin alpha4beta1 antagonists Key Companies
Integrin alpha4beta1 antagonists Key Products
Integrin alpha4beta1 antagonists- Unmet Needs
Integrin alpha4beta1 antagonists- Market Drivers and Barriers
Integrin alpha4beta1 antagonists- Future Perspectives and Conclusion
Integrin alpha4beta1 antagonists Analyst Views
Integrin alpha4beta1 antagonists Key Companies
Appendix